Archer Investment Corp Takes $1.40 Million Position in Bristol Myers Squibb Company $BMY

Archer Investment Corp acquired a new position in shares of Bristol Myers Squibb Company (NYSE:BMY - Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 24,272 shares of the biopharmaceutical company's stock, valued at approximately $1,399,000.

• 2 Buffett Stocks to Load Up On—And 1 to Ditch

A number of other large investors have also recently bought and sold shares of the business. Life Cycle Investment Partners Ltd acquired a new stake in Bristol Myers Squibb during the 4th quarter worth approximately $34,406,000. Lazard Asset Management LLC lifted its position in Bristol Myers Squibb by 23.7% during the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company's stock valued at $116,693,000 after buying an additional 368,193 shares in the last quarter. Axxcess Wealth Management LLC lifted its position in Bristol Myers Squibb by 27.4% during the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company's stock valued at $5,322,000 after buying an additional 21,196 shares in the last quarter. Callan Family Office LLC purchased a new stake in Bristol Myers Squibb during the second quarter worth approximately $3,575,000. Finally, BlackRock Inc. increased its position in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb Trading Down 0.5%

NYSE:BMY opened at $66.62 on Friday. The firm has a market capitalization of $136.09 billion, a P/E ratio of 14.67, a P/E/G ratio of 0.17 and a beta of 0.22. The business has a 50 day simple moving average of $61.76 and a 200 day simple moving average of $59.68. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64.

• Why GRAIL Stock Could Be Biotech’s Next Big Breakout

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion for the quarter, compared to analyst estimates of $11.74 billion. During the same period last year, the company earned $1.46 earnings per share. The firm's revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Equities research analysts predict that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.8%. The ex-dividend date of this dividend was Thursday, July 2nd. Bristol Myers Squibb's dividend payout ratio is currently 55.51%.

More Bristol Myers Squibb News

• Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: The FDA approved Zenbexus (iberdomide), an oral therapy for adults with relapsed or refractory multiple myeloma when used with Johnson & Johnson’s Darzalex and dexamethasone. As the first approved CELMoD therapy in this setting, Zenbexus provides BMY with another potential oncology growth driver and may help diversify its product portfolio. Will ZENBEXUS’s First-in-Class CELMoD Approval Based on MRD-Negative CR Change Bristol Myers Squibb’s Narrative?
• Positive Sentiment: BMY paid Atrium Therapeutics a $15 million milestone after Atrium delivered a lead RNA compound for an undisclosed cardiovascular indication. The payment signals progress in the collaboration and could strengthen investor confidence in BMY’s cardiovascular research pipeline, although the program remains early-stage and details are limited. Can Atrium Therapeutics’ $15 Million Milestone From Bristol-Myers Squibb Validate its RNA Platform?
• Neutral Sentiment: BMY announced a follow-on study for its deucravacitinib program, indicating continued investment in autoimmune diseases. The update supports the company’s longer-term pipeline strategy but does not yet provide a near-term revenue catalyst. Bristol-Myers Squibb Extends Deucravacitinib Program
• Negative Sentiment: Cytokinetics reported a first-ever Phase 3 success in non-obstructive hypertrophic cardiomyopathy, intensifying competition with BMY’s Camzyos cardiovascular franchise. A successful rival could pressure Camzyos’ longer-term growth prospects. Cytokinetics Scores a First-Ever in Its Rivalry Against Bristol Myers
• Negative Sentiment: BMY ended its partnership with Cellares after determining that the company’s manufacturing platform could not produce Breyanzi at commercial scale. The decision may delay planned capacity expansion for the cell therapy and raises questions about Breyanzi’s ability to meet future demand. Bristol-Myers Squibb’s Cellares Exit Raises Questions Over Breyanzi Growth
• Negative Sentiment: SVP Phil Holzer sold 500 BMY shares for approximately $33,750. The relatively small transaction is unlikely to materially affect fundamentals, but it adds a modest negative signal. Bristol Myers Squibb SVP Phil Holzer Sells 500 Shares

Insider Activity

In other news, SVP Phil M. Holzer sold 500 shares of the stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the transaction, the senior vice president directly owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 0.05% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

BMY has been the topic of a number of research reports. JPMorgan Chase & Co. raised their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an "overweight" rating in a research note on Friday, July 31st. Sanford C. Bernstein upgraded Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research note on Wednesday, August 5th. Bank of America dropped their target price on Bristol Myers Squibb from $67.00 to $66.00 and set a "buy" rating on the stock in a report on Friday, July 10th. Weiss Ratings raised Bristol Myers Squibb from a "hold (c+)" rating to a "buy (b-)" rating in a research report on Tuesday, August 18th. Finally, Argus raised shares of Bristol Myers Squibb from a "hold" rating to a "buy" rating and set a $75.00 price objective for the company in a research report on Wednesday, August 5th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Bristol Myers Squibb currently has a consensus rating of "Moderate Buy" and a consensus target price of $66.06.

Get Our Latest Research Report on Bristol Myers Squibb

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Further Reading

• Five stocks we like better than Bristol Myers Squibb
• 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
• IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
• Boeing's $131B F-15 Win: Mach 1 Momentum or Just Altitude?
• Okta Stock Surges 29%—Is $200 the Next Stop?

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Bristol Myers Squibb Right Now?

Before you consider Bristol Myers Squibb, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bristol Myers Squibb wasn't on the list.

While Bristol Myers Squibb currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here